BCYC BICYCLE THERAPEUTICS PLC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1761612 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY194.7%
TTM net income YoY43.4%
TTM EPS YoY43.9%
Revenue 3-yr CAGR49.8%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-189.4%
Net margin-169.8%
FCF margin-211.9%
EBITDA margin-183.8%
Returns
ROE-25.2%
ROA-21.3%
ROIC (approx.)-4,542.9%
Asset turnover0.13x
Leverage & solvency
Liabilities / assets10.9%
Debt / equity0.00x
Current ratio12.09x
Interest coverage-815.60x
Cash quality & payout
Operating cash flow / net income1.24x
Accruals ratio5.0%
Payout ratio—
Capex / revenue2.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $72.59M | $35.27M | $26.98M | $14.46M | $11.70M |
| R&D expense | $240.28M | $172.97M | $156.50M | $81.61M | $44.88M |
| SG&A expense | $79.37M | $72.18M | $60.43M | $49.51M | $32.44M |
| Operating income | -$247.06M | -$209.87M | -$189.95M | -$116.65M | -$65.62M |
| Interest expense | $206,000 | $1.73M | $3.26M | $3.34M | $2.98M |
| Pretax income | -$218.81M | -$173.80M | -$179.21M | -$114.24M | -$68.48M |
| Income tax | $152,000 | -$4.76M | $1.46M | -$1.52M | -$1.66M |
| Net income | -$218.96M | -$169.03M | -$180.66M | -$112.72M | -$66.82M |
| EBITDA | -$240.64M | -$202.70M | -$183.40M | -$112.96M | -$64.21M |
| EPS (basic) | -3.16 | -2.90 | -5.08 | -3.80 | -2.67 |
| EPS (diluted) | -3.16 | -2.90 | -5.08 | -3.80 | -2.67 |
| Dividends declared per share | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Weighted avg. shares (diluted) | 69.28M | 58.21M | 35.59M | 29.66M | 25.06M |
| Balance sheet | |||||
| Cash & equivalents | $628.11M | $880.07M | $526.42M | $339.15M | $438.68M |
| Receivables | $0 | $0 | $0 | $2.04M | $1.00M |
| Current assets | $682.88M | $928.61M | $561.87M | $369.38M | $458.56M |
| PP&E, net | $6.02M | $9.52M | $14.52M | $19.11M | $3.12M |
| Total assets | $717.60M | $956.87M | $595.34M | $410.61M | $479.79M |
| Current liabilities | $56.98M | $67.23M | $69.54M | $53.34M | $36.24M |
| Long-term debt | — | — | $30.70M | $30.32M | $29.87M |
| Total debt | — | — | $30.70M | $30.32M | $29.87M |
| Total liabilities | $107.62M | $163.81M | $224.41M | $139.83M | $133.54M |
| Shareholders' equity | $609.98M | $793.06M | $370.93M | $270.78M | $346.25M |
| Net debt | — | — | -$495.73M | -$308.84M | -$408.81M |
| Shares outstanding | 69.37M | 69.06M | 42.43M | 29.87M | 29.58M |
| Cash flow statement | |||||
| Operating cash flow | -$249.68M | -$164.72M | -$60.63M | -$86.11M | -$14.79M |
| Capital expenditure | $2.35M | $1.24M | $2.93M | $18.99M | $2.03M |
| Free cash flow | -$252.03M | -$165.96M | -$63.56M | -$105.10M | -$16.82M |
| Investing cash flow | -$2.35M | -$1.24M | -$2.93M | -$18.99M | -$2.03M |
| Financing cash flow | -$131,000 | $519.75M | $250.03M | $6.69M | $320.73M |
| Depreciation & amortization | $6.42M | $7.17M | $6.55M | $3.69M | $1.41M |
| Stock-based compensation | $39.46M | $38.08M | $32.48M | $26.78M | $12.08M |
Free plan shows the latest 5 periods; Pro shows all 9 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.